Elicera Therapeutics
1.195 SEK +1.7%1 investor is following this company
Elicera Therapeutics AB is a clinical phase cell and gene therapy company that develops the next generation of immuno-oncology treatments. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T cells and two oncolytic viruses.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
ELIC
Daily low / high price
1.185 / 1.225
SEK
Market cap
41.94M SEK
Turnover
18.81K SEK
Volume
16K
Latest videos
Financial calendar
General meeting
2024-05-16
Interim report
2024-05-16
Interim report
2024-08-29
Interim report
2024-11-14
Annual report
2025-02-13
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Magnus Essand | 16.8 % | 16.8 % |
Di Yu | 16.7 % | 16.7 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Elicera Therapeutics publicerar årsredovisningen för 2023
Kallelse till årsstämma i Elicera Therapeutics AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools